Advertisement

Drugs Under Preclinical and Clinical Testing for the Treatment of Infections Caused due to Staphylococcus aureus: An Update

  • Manjulika Shukla
  • Isha Soni
  • Arunava Dasgupta
  • Sidharth Chopra
Chapter

Abstract

Staphylococcus aureus is a significant pathogen of interest worldwide owing to its increasing drug resistance and dwindling antimicrobial armamentarium available against it. Although it typically causes uncomplicated infections, recently increasingly it has been linked to serious community and nosocomial infections ranging from boils to bloodstream infections to endocarditis. Even though there are a number of antibiotics available for the treatment of uncomplicated S. aureus infections, the advent of drug resistance has complicated the picture due to decreasing options available for the treatment coupled with increased transmission of drug-resistant strains in the community. Even though the drug discovery pipeline has recently been augmented with the discovery of some new molecules active against S. aureus, the true status is anemic owing to lack of molecules acting via new mechanism of action. This chapter describes the various molecules which are in preclinical and clinical development against S. aureus and depicts the various challenges as well as lacunae in them.

Keywords

Staphylococcus Preclinical Drugs MRSA 

Notes

Acknowledgments

This manuscript CSIR-CDRI communication number 9662.

References

  1. Boucher HW, Talbot GH, Bradley JS, Edwards GD, Rice LB et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12CrossRefGoogle Scholar
  2. Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE (2013) Abstract F-1216. 53rd annual interscience conference on antimicrobial agents and chemotherapy; September, Denver, COGoogle Scholar
  3. Chen H, Olson AS, Dussault AH, Du L (2015) Fatty acyl incorporation in the biosynthesis of WAP- 8294A, a group of potent anti-MRSA cyclic lipodepsipeptides. RSC Adv 5:105753–105759CrossRefGoogle Scholar
  4. Chopra S, Dasgupta A (2014) Eravacycline: a monograph. Drugs Future 39:247CrossRefGoogle Scholar
  5. Colca JR, McDonald WG, Waldon DJ et al (2003) Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 278:21972–21979CrossRefGoogle Scholar
  6. Craig WA, Andes DR, Stamstad T (2010) In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob Agents Chemother 54:5092–5098CrossRefGoogle Scholar
  7. Farrell DJ, Liverman LC, Biedenbach DJ et al (2011a) JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother 55:3631–3634CrossRefGoogle Scholar
  8. Farrell DJ, Robbins M, Rhys-Williams W et al (2011b) Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother 55:1177–1181CrossRefGoogle Scholar
  9. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK (2017) In vitro activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother 61:e02047–e02016CrossRefGoogle Scholar
  10. Fernandes P, Martens E, Bertrand D, Pereira D (2016) The solithromycin journey-it is all in the chemistry. Bioorg Med Chem 24:6420–6428CrossRefGoogle Scholar
  11. Gordeev MF, Yuan ZY (2014) New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem 57:4487–4497CrossRefGoogle Scholar
  12. Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J (2012) Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig 32(7):475–486CrossRefGoogle Scholar
  13. Hedge SS et al (2007) Efficacy of Td-1792, a novel multivalent glycopeptide, against Gram-positive pathogens in the neutropenic thigh model, abstr. A-42. Abstr. 47th intersci. conf. antimicrobial agents and chemotherapy. Chicago, ILGoogle Scholar
  14. http://adisinsight.springer.com/drugs/800016734. Last accessed 18 June 2017Google Scholar
  15. http://adisinsight.springer.com/drugs/800019661. Last accessed 18 June 2017Google Scholar
  16. http://adisinsight.springer.com/drugs/800022726. Last accessed 18 June 2017Google Scholar
  17. http://adisinsight.springer.com/drugs/800027159. Last accessed 18 June 2017Google Scholar
  18. http://adisinsight.springer.com/drugs/800030124. Last accessed 18 June 2017Google Scholar
  19. http://adisinsight.springer.com/drugs/800035856. Last accessed 18 June 2017Google Scholar
  20. http://adisinsight.springer.com/drugs/800044518. Last accessed 18 June 2017Google Scholar
  21. http://www.theravance.com/bacterial. Last accessed 18 June 2017Google Scholar
  22. http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. Last accessed on 18 June 2017Google Scholar
  23. http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/Google Scholar
  24. https://www.investor.cempra.com/releasedetail.cfm?ReleaseID=1014395. Last accessed 18 June 2017Google Scholar
  25. https://www.jmilabs.com/data/posters/ICAAC2014/F-970.PDF. Last accessed 18 June 2017Google Scholar
  26. Ippolito JA, Kanyo ZF, Wang D et al (2008) Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 51:3353–3356CrossRefGoogle Scholar
  27. Jeong J-W, Jung S-J, Lee H-H, Kim Y-Z, Park T-K, Cho Y-L et al (2010) In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother 12:5359–5362CrossRefGoogle Scholar
  28. Kaplan N, Albert M, Awrey D et al (2012) Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother 56:5865–5874CrossRefGoogle Scholar
  29. Kim BY, Sohn YT (2011) Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Arch Pharm Res 34:775–779CrossRefGoogle Scholar
  30. Kim EJ, Shin WH, Kim KS, Han SS (2004) Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem Toxicol 27:295–307CrossRefGoogle Scholar
  31. Kumar K, Chopra S (2013) New drugs for methicillin-resistant Staphylococcus aureus: an update. J Antimicrob Chemother 68:1465–1470CrossRefGoogle Scholar
  32. Lawrence L, Danese P, DeVito J et al (2008) In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother 52:1653–1662CrossRefGoogle Scholar
  33. Leach KL, Swaney SM, Colca JR et al (2007) The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 26:393–392CrossRefGoogle Scholar
  34. Leuthner KD, Vidaillac C, Cheung CM et al (2010) In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob Agents Chemother 54:3799–3803CrossRefGoogle Scholar
  35. Liu F, Myers AG (2016) Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics. Curr Opin Chem Biol 32:48–57CrossRefGoogle Scholar
  36. McLaws FB, Larsen AR, Skov RL et al (2011) Distribution of fusidic acid resistance determinants in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:1173–1176CrossRefGoogle Scholar
  37. Mensa B, Howell G, Scott R, DeGrad WF (2014) Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58:5136–5145CrossRefGoogle Scholar
  38. Noel GJ, Draper MP, Hait H et al (2012) A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5650–5654CrossRefGoogle Scholar
  39. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak J-H (2007a) Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 60:568–564CrossRefGoogle Scholar
  40. Park HS, Yoon YM, Jung SJ et al (2007b) Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 60:568–564CrossRefGoogle Scholar
  41. Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS, Chugh Y et al (2004) Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 48:4754–4761CrossRefGoogle Scholar
  42. Remy JM, Tow-Keogh CA, McConnell TS et al (2012) Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 67:2814–2820CrossRefGoogle Scholar
  43. Ross JE, Scangarella-Oman NE, Miller LA et al (2011) Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J Clin Microbiol 49:3928–3930CrossRefGoogle Scholar
  44. Rubinchik E, Schneider T, Elliott M et al (2011) Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob Agents Chemother 55:2743–2754CrossRefGoogle Scholar
  45. Schneider P, Hawser S, Islam K (2003) Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13:4217–4221CrossRefGoogle Scholar
  46. Stryjewski ME, Potgieter PD, Li Y-P et al (2012) TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5476–5483CrossRefGoogle Scholar
  47. Stubbings W, Leow P, Yong GC et al (2011) In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 55:4394–4397CrossRefGoogle Scholar
  48. Tenover FC, Tickler I, Armstrong ES et al (2011) Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents 38:352–354CrossRefGoogle Scholar
  49. Xiao XY, Hunt DK, Zhou J et al (2012) Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597–595CrossRefGoogle Scholar
  50. Yum JH, Kim CK, Yong D et al (2007) In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother 51:2591–2593CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Manjulika Shukla
    • 1
  • Isha Soni
    • 1
  • Arunava Dasgupta
    • 1
  • Sidharth Chopra
    • 1
  1. 1.Division of MicrobiologyCSIR-Central Drug Research InstituteLucknowIndia

Personalised recommendations